Drug Information

Drug General Information
Drug ID
D03DJC
Former ID
DNC007239
Drug Name
2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528738]
Formula
C15H16N2O3
Canonical SMILES
C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC=C3N
InChI
1S/C15H16N2O3/c16-13-4-2-1-3-12(13)14-9-11(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8,16H2
InChIKey
SGCZGVONFZVNLU-UHFFFAOYSA-N
PubChem Compound ID
16203354
Target and Pathway
Target(s) DNA-dependent protein kinase catalytic subunit Target Info Inhibitor [528738]
KEGG Pathway Non-homologous end-joining
Cell cycle
NetPath Pathway IL1 Signaling Pathway
Pathway Interaction Database DNA-PK pathway in nonhomologous end joining
Coregulation of Androgen receptor activity
Class I PI3K signaling events mediated by Akt
BARD1 signaling events
Reactome Nonhomologous End-Joining (NHEJ)
WikiPathways DNA Damage Response
Non-homologous end joining
FAS pathway and Stress induction of HSP regulation
Cytosolic sensors of pathogen-associated DNA
Retinoblastoma (RB) in Cancer
Prostate Cancer
Double-Strand Break Repair
Cell Cycle
miRNA Regulation of DNA Damage Response
References
Ref 528738J Med Chem. 2007 Apr 19;50(8):1958-72. Epub 2007 Mar 20.Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Ref 528738J Med Chem. 2007 Apr 19;50(8):1958-72. Epub 2007 Mar 20.Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.